Article Figures & Data
Figures
- Figure 1
The comparison of plasma CHIT levels in patients with CHF and controls. CHF, chronic heart failure; CHIT, chitotriosidase.
- Figure 2
The comparison of plasma CHIT levels according to etiology of heart failure. CHIT, chitotriosidase; HF, heart failure.
- Figure 3
The correlation between CHIT and NT-proBNP in heart failure according to underlying etiology. CHIT, chitotriosidase; HF, heart failure; NT-proBNP, N-terminal pro brain natriuretic peptide.
Tables
- Table 1
Baseline characteristics, laboratory data and medications
Patients (n=36) Controls (n=27) P value Baseline characteristics Mean age (years) 63.17±10.18 61.33±8.73 0.455 Males, n (%) 18 (50) 12 (44) 0.662 Body mass index (kg/m2) 28.38±5.13 28.91±4.97 0.682 Hypertension, n (%) 17 (47) 9 (33) 0.268 Diabetes mellitus, n (%) – 14 (39) 0.0001 Smoking, n (%) 3 (8) 5 (19) 0.272 Systolic blood pressure (mm Hg) 119.89±13.44 117.37±13.57 0.466 Diastolic blood pressure (mm Hg) 76.72±10.56 73.48±8.73 0.200 Heart rate (beats/min) 74.58±13.24 70.78±13.29 0.177 Atrial fibrillation, n (%) 10 (28) – 0.003 LVEDD (mm) 60.86±5.56 46.19±3.78 <0.001 LVESD (mm) 49.11±6.40 29.04±3.03 <0.001 LVEF (%) 27.27±5.23 60.17±3.21 <0.001 Laboratory findings FPG (mg/dL) 115.33±28.64 95.44±10.57 0.002 Creatinine (mg/dL) 0.96±0.16 0.72±0.10 <0.001 GFR (mL/min/m2) 75.15±13.77 89.04±13.69 <0.001 Sodium (mEq/L) 139.22±3.46 140.74±1.81 0.028 T-chol (mg/dL) 188.78±46.34 197.11±39.71 0.456 TG (mg/dL) 163.64±77.40 117.41±64.47 0.002 LDL-C (mg/dL) 110.17±31.27 118.56±30.65 0.292 HDL-C (mg/dL) 40.61±7.27 54.85±13.43 <0.001 Hemoglobin (g/L) 137.00±13.00 142.50±13.30 0.08 WBC (cells/μL) 9.07±2.07 6.6±1.46 <0.001 Albumin (g/dL) 4.27±0.26 4.56±0.25 <0.001 NT-proBNP (pg/mL) 595.31±428.11 78.13±30.47 <0.001 Chitotriosidase (ng/mL) 931.25±461.39 232.79±61.28 <0.001 Medication, n (%) ACE inhibitor/ARB 27 (75) 8 (30) <0.001 Beta-blockers 32 (89) 2 (7) <0.001 Statins 13 (36) 1 (4) 0.002 Loop diüretics 23 (64) – <0.001 Aldosterone antagonist 19 (53) – <0.001 Antiplatelet agents 34 (94) 5 (19) <0.001 Digoxine 9 (25) – <0.001 ACE, angiotensin-converting enzyme; ; ARB, angiotensin receptor blocker; FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.
- Table 2
Characteristics of study patients according to the etiology
IHF (n=20) NIHF (n=16) P value Baseline characteristics Mean age (years) 63.45±10.49 62.81±10.11 0.855 Males, n (%) 10 (50) 8 (50) 1.000 Body mass index (kg/m2) 29.19±6.13 27.38±3.45 0.272 Hypertension, n (%) 10 (50) 7 (44) 0.709 Diabetes mellitus, n (%) 9 (45) 5 (31) 0.400 Smoking, n (%) 2 (10) 1 (6) 1.000 Systolic blood pressure (mm Hg) 120.65±16.78 118.94±7.92 0.69 Diastolic blood pressure (mm Hg) 75.20±12.25 78.63±7.97 0.404 Heart rate (beats/min) 73.15±12.03 76.38±14.81 0.476 Atrial fibrillation, n (%) 5 (25) 5 (31) 0.722 LVEDD (mm) 61.90±6.46 59.56±4.02 0.386 LVESD (mm) 50.45±7.39 47.44±4.60 0.290 LVEF (%) 25.57±5.14 29.39±4.67 0.027 NYHA I–II, n (%) 6 (30) 10 (63) 0.05 NYHA III–IV, n (%) 14 (70) 6 (37) 0.05 Laboratory findings FPG (mg/dL) 121.90±29.01 107.13±26.81 0.062 Creatinine (mg/dL) 1.02±0.19 0.89±0.07 0.012 GFR (mL/min/m2) 70.24±14.68 81.29±9.84 0.011 Sodium (mEq/L) 139±3.29 139.5±3.74 0.44 T-chol (mg/dL) 177.35±43.16 203.06±47.54 0.099 TG (mg/dL) 167.40±90.53 158.94±59.64 0.888 LDL-C (mg/dL) 108.35±32.05 112.44±31.14 0.703 HDL-C (mg/dL) 38.45±7.81 43.31±5.65 0.02 Hemoglobin (g/L) 139.40±13.10 133.90±12.60 0.215 WBC (cells/μL) 9.70±2.07 8.29±1.84 0.049 Albumin (g/dL) 4.24±0.27 4.30±0.26 0.508 NT-proBNP (pg/mL) 792.87±461.26 348.36±202.61 0.001 Chitotriosidase (ng/mL) 1139.28±495.22 671.22±237.21 0.002 Medication, n (%) ACE inhibitor/ARB 13 (65) 14 (88) 0.245 Beta-blockers 18 (90) 14 (88) 0.813 Statins 12 (60) 1 (6) 0.001 Loop diüretics 15 (75) 8 (50) 0.121 Aldosterone antagonist 10 (50) 9 (56) 0.709 Antiplatelet agents 18 (90) 16 (100) 0.492 Digoxine 5 (25) 4 (25) 1.000 ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; IHF, ischemic heart failure; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NIHF, non-ischemic heart failure; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; NYHA, New York Heart Association; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.
- Table 3
The correlation analysis of chitotriosidase in patients with heart failure
Variables R P value Mean age 0.515 0.001 Body mass index −0.146 0.397 Systolic blood pressure −0.082 0.635 Diastolic blood pressure −0.186 0.277 Heart rate 0.164 0.340 LVEDD 0.008 0.962 LVESD 0.076 0.660 LVEF −0.491 0.002 FPG 0.183 0.284 Creatinine 0.345 0.04 GFR −0.693 <0.001 Sodium −0.267 0.116 T-chol −0.057 0.743 TG 0.226 0.229 LDL-C 0.101 0.557 HDL-C −0.068 0.692 Hemoglobin −0.241 0.157 WBC 0.680 <0.001 Albumin −0.422 0.01 NT-proBNP 0.969 <0.001 FPG, fasting plasma glucose; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; NT-proBNP, N-terminal pro hormone brain natriuretic peptide; T-chol, total cholesterol; TG, triglycerides; WBC, white blood cells.
